[
  {
    "timestamp": "2026-02-05 15:10:50",
    "diff": "Initial data collection"
  },
  {
    "timestamp": "2026-02-10 07:03:50",
    "diff": "Field `statusModule.statusVerifiedDate` changed from `2025-09` to `2026-01`\nField `statusModule.primaryCompletionDateStruct.date` changed from `2027-03-21` to `2029-04-06`\nField `statusModule.lastUpdateSubmitDate` changed from `2025-09-25` to `2026-02-03`\nField `statusModule.lastUpdatePostDateStruct.date` changed from `2025-09-30` to `2026-02-05`\nField `descriptionModule.detailedDescription` changed from `The master protocol will include 3 sub-studies, each focused on a specific disease population.\n\n* Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.\n* Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.\n* Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+\n\nEach sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).` to `The master protocol will include 3 sub-studies, each focused on a specific disease population.\n\n* Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.\n* Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.\n* Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+\n\nEach sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).`\nField `outcomesModule.primaryOutcomes.[1]description` changed from `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1` to `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1`\nField `outcomesModule.secondaryOutcomes.[2]description` changed from `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1 as assessed by Investigator.` to `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1.`\nField `contactsLocationsModule.locations.[10]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[11]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[12]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[17]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[26]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[33]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[34]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[36]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[37]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[38]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[41]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[44]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[48]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`\nField `armsInterventionsModule.armGroups.[0]` changed from `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`\nField `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['DS-1062']}` to `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['DS-1062']}`\nField `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['AZD2936']}` to `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['AZD2936']}`\nField `armsInterventionsModule.armGroups.[2]` changed from `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}` to `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}`\nField `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`\nField `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['Cyramza']}` to `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['Cyramza']}`"
  }
]